Active Biotech strengthens its financial position: rights

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
Active Biotech strengthens its financial position: rights issue of approximately SEK 225 million

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, AUSTRALIA, HONG KONG, JAPAN, CANADA, SINGAPORE, SOUTH AFRICA OR NEW ZEALAND OR IN ANY OTHER JURISDICTION IN WHICH THE DISTRIBUTION OF THIS PRESS RELEASE WOULD BE UNLAWFUL. On 4 November 2014, the board of directors of Active Biotech AB (publ) ("Active Biotech" or the "Company") resolved, subject to approval by the shareholders' meeting, on a rights issue with pre-emptive rights of approximately SEK 225 million, at full subscription. The rights issue strengthens Active Biotech's financial position and its position in discussions with existing and new potential new partners. * The shareholders of the Company have pre-emptive rights to subscribe for the new shares, whereby five existing shares entitle the subscription of one new share. * The subscription price is SEK 15 per share. Subscription shall be made during the period 8 - 22 December 2014. * Active Biotech's largest shareholders, with total holdings of approximately 49 per cent of the Company's shares and votes, have undertaken to subscribe for their respective pre-emptive parts of the rights issue. * Extraordinary shareholders' meeting to be held on 1 December 2014 for approval of the board's resolution. Background and reasons The Board of Directors of Active Biotech has decided to focus the company's resources on the two projects in late clinical phase and on new proprietary molecules discovered in-house. After completed clinical studies, no further scientific activities will be performed with respect to the projects ANYARA and paquinimod. The two projects in late clinical phase are both out-licensed. However, the company has retained all the commercial rights for tasquinimod in North and South America as well as Japan for out-licensing once Phase III results have been obtained. The laquinimod project is focused on the treatment of neurodegenerative diseases. The three diseases in which clinical development is ongoing are relapsing remitting multiple sclerosis (RRMS), primary progressive multiple sclerosis (PPMS) and Huntington's disease. Study results are expected in the first six months of 2016 which, if positive, will be considered pivotal. The project has undergone, and is currently undergoing, a highly comprehensive clinical development program, and completed and ongoing investments in the project by Active Biotech and its partner are estimated to total about SEK 5 billion. The tasquinimod project is being developed for the treatment of cancer, primarily metastatic Castrate Resistant Prostate Cancer (mCRPC). Study results are expected in the first six months of 2015 which, if positive, will be considered pivotal. Completed and ongoing investments in the project by Active Biotech and its partner are estimated to total about SEK 2 billion. In addition, Active Biotech is pursuing a preclinical project, ISI. This project is based on preclinical studies and has potential treatment applications in both degenerative diseases and cancer. The initial selection of a candidate drug (CD) for cancer therapy is planned for 2015. The rights issue at hand will provide Active Biotech with the financial stability required pending the outcome of the ongoing Phase III studies, where both projects have significant commercial potential. If the pivotal results for tasquinimod are obtained in the first six months of 2015, the Company is of the opinion that this financial stability will be required to maximize the project's commercial value in negotiations with potential partners for the Company's own territories. The Company's current liquidity and this proposed new share issue, combined with revenues from existing and anticipated agreements are, according to present-day plans, assumed to be sufficient to finance operations until such time as a positive cash flow can be generated. The rights issue On 4 November 2014, the Board of Directors of Active Biotech resolved, subject to approval by the shareholders' meeting, to increase the Company's share capital with not more than SEK 56,482,529.18 through issue of not more than 14,984,716 new shares. The subscription price is SEK 15 per share, whereby Active Biotech will be provided with approximately SEK 225 million at full subscription, before issue expenses. The shareholders of the Company have pre-emptive rights to subscribe for the new shares, whereby five existing shares entitle to subscription for one new share. Shares not subscribed for with pre-emptive rights shall be allocated to persons that have subscribed for shares by exercise of subscription rights and declared their interest to subscribe for shares also without pre-emptive rights, whereby allocation shall be made in relation to the number of subscription rights such persons have exercised for subscription. Thereafter, allocation shall be made to persons that have declared their interest to subscribe for shares without pre- emptive rights. The record date for the right to participate in the rights issue is 4 December 2014. Subscription for new shares shall be made during the period 8 - 22 December 2014. The Company's largest shareholders MGA Holding AB, Nordstjernan AB and Investor AB through Duba AB, as well as Peter Thelin (privately and through companies), with a combined holding of approximately 49 per cent of the number of shares and votes of the Company, have undertaken to subscribe for their respective pre- emptive parts of the rights issue. The resolution of the board is subject to approval by the extraordinary shareholders' meeting that will be held on 1 December 2014. The above-mentioned shareholders have also undertaken to vote in favor of the rights issue at the shareholders' meeting. Notice to the shareholders' meeting will be published through a separate press release today. A prospectus relating to the rights issue will be made public before the commencement of the subscription period. Indicative timetable +---------------+--------------------------------------------------------------+ |1 December |Extraordinary shareholders' meeting for approval of the| | |board's resolution. | +---------------+--------------------------------------------------------------+ |2 December |Last day of trading in the Active Biotech share including the| | |right to participate in the rights issue. | +---------------+--------------------------------------------------------------+ |3 December |First day of trading in the Active Biotech share excluding the| | |right to participate in the rights issue. | +---------------+--------------------------------------------------------------+ |4 December |Record date for the right to participate in the rights issue. | +---------------+--------------------------------------------------------------+ |8 - 18 December|Trading in subscription rights. | +---------------+--------------------------------------------------------------+ |8 - 22 December|Subscription period. | +---------------+--------------------------------------------------------------+ Advisor Advokatfirman Vinge is legal advisor to Active Biotech in connection with the rights issue. For further information, please contact: Tomas Leanderson, CEO Tel: +46 (0)46 19 20 95 E-mail: tomas.leanderson@activebiotech.com Hans Kolam, CFO Tel: +46 (0)46 19 20 44 E-mail: hans.kolam@activebiotech.com Active Biotech AB Box 724, SE-220 07 Lund, Sweden Phone +46 (0)46 19 20 00 Fax +46 (0)46 19 11 00 Active Biotech AB (NASDAQ OMX NORDIC: ACTI) is a biotechnology company with focus on neurodegenerative diseases and cancer. In pivotal phase is laquinimod, an orally administered small compound with unique immunomodulatory properties for the treatment of multiple sclerosis and tasquinimod, an orally administered compound with immunomodulatory, metastatic restraining properties for the treatment of prostate cancer. The pre-clinical project ISI has the aim of generating new, patentable chemical compounds for the treatment of the diseases within the company's areas of focus. Please visit www.activebiotech.com for more information Active Biotech is required to publish the information contained in this press release in accordance with the Swedish Securities Market Act. This information was provided to the media for publication at 8:31 am CET on 5 November 2014. Important information This press release is not an offer to subscribe for shares in Active Biotech. A prospectus relating to the rights issue referred to in this press release will be made public by the Company prior to the commencement of the subscription period. This press release is not a prospectus and investors should not subscribe for or purchase any securities referred to in this press release, except on the basis of information provided in the prospectus. This press release may not be made public, released or distributed, directly or indirectly, in or into the United States, Australia, Hong Kong, Japan, Canada, Singapore, South Africa or New Zealand or in any other jurisdiction in which the distribution of this press release would be unlawful. Further, this press release does not constitute an offer to sell new shares, paid subscribed for shares ("BTA") or subscription rights to any person in any jurisdiction in which it is unlawful to make such offer to such person or where such action would require additional prospectuses, registration or other measures other than those pursuant to Swedish law. The prospectus, application form and other documents associated with the rights issue may not be distributed in or to any country where such distribution or the rights issue would require such measures set forth in the preceding sentence or be in violation of the regulations of such country. The new shares, BTAs and subscription rights have not been recommended by a United States federal or state securities commission or regulatory authority. No new shares, BTAs, subscription rights or other securities issued by Active Biotech have been or will be registered under the U.S. Securities Act of 1933, or under the securities legislation in any state of the United States or any province in Canada. Accordingly, no new shares, BTAs, subscription rights or other securities issued by Active Biotech may be transferred or offered for sale in the United States or Canada, other than in such exceptional cases that do not require registration. The securities issued in the rights issue will not be offered to the public in the United States. Active Biotech has not authorized any offer of securities to the public in any country in the European Economic Area ("EEA") other than Sweden. In other member states in the EEA which have implemented the Directive 2003/71/EC (the "Prospectus Directive") (each, a "Relevant Member State"), no action has been undertaken and will not be undertaken to make an offer of securities to the public requiring publication of a prospectus in any Relevant Member State. As a result, the securities may only be offered in Relevant Member States to (a) any legal entity which is a qualified investor as defined in the Prospectus Directive; or (b) any person falling within Article 3(2) of the Prospectus Directive. The rights issue is only directed at (i) persons who are outside the United Kingdom or (ii) persons who have professional experience in matters relating to investments falling within Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (the "Order") and (iii) high net worth entities, and other persons to whom it may lawfully be communicated, falling within Article 49(2) of the Order (all such persons together being referred to as "relevant persons"). The securities issued in the rights issue will only be available to and will only be engaged with, relevant persons. Any person who is not a relevant person should not act or rely on this document or any of its contents. [HUG#1868652]

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Thanksgiving Dog Safety Is a Pet Care Reality Check

Updated Category News Views 0

A crowded Thanksgiving kitchen can turn a well-behaved dog into a scavenger with lousy odds. Camp Bow Wow’s holiday guidance is not pretending the meal itself is the problem; the trouble is that a house full of distracted people, rich food and unsecured trash creates a pile of easy mistakes. For pet owners, that is a fair reminder. For anybody watching the pet-care...

Continue Reading
Peptide Labels Cannot Substitute for Clinical Care

Updated Category News Views 9

A Label Is Not a Care Plan Those three little words, research use only, carry far more weight than a flashy product page would have people believe. The HelloNation article featuring wellness expert Andres Giraldo makes a plain but necessary distinction: a research-use-only, or RUO, label does not turn a peptide into prescribed treatment, and it sure does not establish...

Continue Reading
Washington-to-Asia Advisory Deal Targets Policy Risk

Updated Category News Views 0

Policy bottlenecks are becoming a cost center across Southeast Asia. That is the plain-English backdrop for the strategic partnership announced November 18, 2026, by Beacon Global Strategies and Vriens & Partners. Neither firm is selling a factory, a chip design, or a new energy project. They are selling something companies increasingly cannot afford to improvise: a...

Continue Reading
Spruce Spins Adrenyx En Route to Nasdaq in 2027

Updated Category News Views 206

New Frontiers: Adrenyx Biosciences Takes Shape Well, here's a new chapter in biotech drama. Spruce Biosciences, a name you might have tangled with if you're into tickers like NASDAQ:SPRB, just carved out a niche with the birth of Adrenyx Biosciences. The play? A separate company eyeing the endocrinology space, setting its sights on tackling congenital adrenal hyperplasia...

Continue Reading
Tactical Tomahawk Motor Deal Puts Propulsion in Focus

Updated Category News Views 31

A missile program lives or dies on unglamorous hardware, and solid rocket motors are about as unglamorous as it gets until somebody cannot build enough of them. Raytheon has awarded Ursa Major and Avio USA a joint contract to develop solid rocket motors for the U.S. Navy’s Tactical Tomahawk missile program. That is the whole headline, and it matters more than the thin...

Continue Reading
Insider Risk Makes Human Judgment a Security Priority

Updated Category News Views 127

A badge, a password, and a locked gate can all look reassuring right up until the person holding them starts to crack. Signpost Six's new report, The Psychology of Insider Risk, lands on an uncomfortable truth: the most consequential security weakness may not be a system at all. It may be an employee under strain, in conflict, in debt, making a mistake, or being quietly...

Continue Reading
Google Search Data Sharing Faces a Privacy Reality Check

Updated Category News Views 91

Search queries are messy little confessions, and that is exactly why this case deserves more than a bureaucratic shrug. Woodway Assurance's independent assessment says Google's search-query data could be treated as anonymized for sharing under the Digital Markets Act, but only if the European Commission tightens parts of its July 2026 framework. That is not a clean bill...

Continue Reading
Kawneer’s OptiQ Window Wins a Useful Design Signal

Updated Category News Views 49

Three Nods, One Very Practical Product Claim Windows rarely stir much excitement outside an architect’s specification binder, but Kawneer has put together a respectable run with its OptiQ Offset Fixed/Projected Series Window. On November 18, 2026, the architectural aluminum-systems maker said the product had won in the Windows and Doors category at both the 2026...

Continue Reading
A Decade of Giving: Light the World Initiative's Impact

Updated Category News Views 157

The Red Kiosk Revolution It's not every day that a church initiative pops up in global conversations, but here we are—ten years into the Light the World initiative by The Church of Jesus Christ of Latter-day Saints. What's interesting is how these little kiosks, like silent ambassadors, have become a staple in 145 spots this holiday season, spanning continents. Each...

Continue Reading
Anycubic Pushes Toward a Smoother 3D Printing Ecosystem

Updated Category News Views 46

Friction Is the Enemy in Consumer 3D Printing A printer that makes a beautiful object only after three failed attempts is not a consumer product; it is a weekend argument with plastic. That is the useful lens for Anycubic's Formnext 2026 showing in Frankfurt on November 18. The company is not merely rolling out FDM and resin machines at Booth F01 in Hall 12.0. It is...

Continue Reading

Top 5 Most Recently Viewed Articles

Bioretec's Innovative Annual Report Showcases New Progress

Updated Category News Views 188

Bioretec Ltd's Annual Report Overview Bioretec Ltd has recently published its annual report for 2024, offering insights into the company's growth and achievements over the past year. This report showcases the advancements made in biodegradable orthopedic implants, positioning the company at the forefront of innovative healthcare solutions. Company Highlights Bioretec...

Continue Reading
Market Overview: Asia Stocks See Fluctuations Amid Election Fears

Updated Category News Views 251

Market Dynamics in Asia: A Closer Look In recent trading sessions, Asian stocks demonstrated muted movements in response to an absence of compelling trading signals, while Japanese shares experienced a notable decline driven by impending democratic choices. Investors are particularly focused on the Japanese electoral scene, which is expected to significantly influence...

Continue Reading
TScan Therapeutics Secures $52.5 Million Loan to Support Growth

Updated Category News Views 113

TScan Therapeutics Secures $52.5 Million Loan from Silicon Valley Bank WALTHAM, Mass. — TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage biotechnology company dedicated to developing innovative therapies for cancer treatment, has announced an exciting milestone. The company has entered into a term loan facility with Silicon Valley Bank (SVB) that offers up to...

Continue Reading
Celebrating Four Years of SpaceX's Starlink Internet Service

Updated Category News Views 385

Four Years of Starlink Connectivity Four years ago, SpaceX, under the visionary leadership of Elon Musk, began its journey in satellite internet services by activating Starlink for its first paying customer. This significant milestone was established on a date that marks the beginning of a transformative era for internet connectivity. Impact of Starlink on Global Internet...

Continue Reading
AllenComm Receives Esteemed Recognition in eLearning Field

Updated Category News Views 167

AllenComm Earns Top Honor for eLearning Localization AllenComm, a prominent player in the realm of innovative learning experiences, has recently been recognized as one of the Top Content Providers for eLearning Localization by a well-regarded industry source. This accolade reflects the company's dedication to delivering high-quality, effective educational solutions that...

Continue Reading